The post FDA reversals on UniQure, Moderna approvals worry investors appeared on BitcoinEthereumNews.com. Investors are concerned about the fates of multiple experimentalThe post FDA reversals on UniQure, Moderna approvals worry investors appeared on BitcoinEthereumNews.com. Investors are concerned about the fates of multiple experimental

FDA reversals on UniQure, Moderna approvals worry investors

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration. 

The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from UniQure, a gene therapy for Hunter syndrome from Regenxbio and a drug for a blood condition from Disc Medicine. The agency initially refused to review Moderna‘s flu shot before reversing course. 

In each case, the FDA took issue with the evidence the companies were using to support their applications. Some of the studies didn’t test the drugs against a placebo. Some companies didn’t directly measure the drug’s efficacy, instead relying on other factors like biomarkers to predict how well the treatment might work. 

And in every case, the companies have accused the FDA of reversing its previous guidance. That’s making investors wary that a more unpredictable FDA could jeopardize the future of other treatments for hard-to-treat diseases.

“What investors and key stakeholders are hoping to see from the FDA is consistency, and it does feel that that seems to be lacking at the moment,” said RBC Capital Markets analyst Luca Issi.

In recent years, the FDA appeared willing to accept drugs for rare diseases that showed promise in less rigorous studies than the gold standard randomized, double-blind placebo controlled trials. That meant helping bring treatments more quickly to patients who have conditions where time passing could mean the loss of functions like walking or talking, or even death. It also drew controversy from critics who said that policy brought false hope to patients.

The FDA’s recent decisions has left investors wondering whether the agency’s bar has changed for other drugs in the pipeline. In the case of UniQure, the FDA asked the company to run a new study that directly compares its treatment to placebo. UniQure said that contradicts the agency’s past guidance that the company could seek approval with trial data that compared UniQure’s treatment to an external database of people with Huntington’s disease.

One former FDA official who spoke to CNBC on the condition of anonymity to speak freely called this the worst type of regulatory uncertainty, because companies say they are being told one thing then experiencing another.

Analysts point to several other companies they’re watching, including Dyne Therapeutics, which is advancing a drug for Duchenne muscular dystrophy; Taysha Gene Therapies, which is developing a gene therapy for Rett syndrome; Wave Life Sciences, which is working on a treatment for a liver condition; and Lexeo Therapeutics, which is developing a gene therapy for Friedreich Ataxia. All of those companies’ stocks are down this year.

A Dyne spokesperson said the company has maintained a frequent, positive and collaborative dialogue with a consistent set of reviewers over the past 18 months, and that it’s confident in its development strategy and path forward based on the strength of its clinical results, rigor of its trial design and continued engagement with the FDA. Taysha, Wave and Lexeo declined to comment.

One looming decision that Stifel analyst Paul Matteis is tracking is a drug candidate from Denali Therapeutics for Hunter syndrome, a rare disease that causes physical defects like hearing loss and joint problems, as well as cognitive issues. The company’s application for accelerated approval relies on a trial that wasn’t randomized and data showing the drug decreases levels of a biomarker associated with the condition.

To Matteis, the dataset is harder to argue with than UniQure’s, and there’s not much risk with the technology used.

“So if they don’t approve that, I don’t know,” Matteis said. “I mean, I already think there’s been a pretty significant change in the regulatory standard of rare disease, but if they don’t approve Denali, if I was at a company I’d almost be saying to myself, ‘Can we really be confident in running an open-label study?'”

In a statement to CNBC, Denali Therapeutics CEO Ryan Watts said the company continues having constructive discussions with the FDA, and it’s confident in the strength of the data package it submitted. The FDA delayed its review of the application by three months and is now expected to decide by April 5.

Some investors feel a clash between the flexibility FDA leaders like Commissioner Marty Makary are pledging publicly and the recent decisions the agency has made, said RBC Capital Markets’ Issi. That’s leading some to discount the probability of success for companies whose paths to the market rely on some level of flexibility in the data the agency will accept, said Stifel’s Matteis.

For companies whose data are straightforward, the path looks clear, said Christiana Bardon, managing partner of MPM BioImpact. The question to her is how much the FDA should accelerate the process to bring drugs to patients as rapidly as possible for diseases with massive unmet needs.

One senior FDA official, speaking to reporters Thursday on the condition of anonymity to speak freely, said the FDA hasn’t changed its position that biomarkers reasonably likely to predict efficacy can and will get accelerated approval, and that non-randomized data can get full approval. To this official, the bar is clear.

“If you make a treatment for Alzheimer’s or Huntington’s, and you take someone who’s severely ill and you give them that therapy, and they start doing better immediately and dramatically,” the official said. “You take someone in a nursing home with Alzheimer’s, and then they walk out of it, or somebody with end-stage Huntington’s, and they suddenly have no symptoms of Huntington’s, you will get a full regulatory approval with two or three patients.

“We only ask for randomized data when a condition is heterogeneous, when the will to believe is strong, when the therapy is invasive or potentially harmful, when the effect size is difficult to detect, and when the possibility you are fooling yourself is high,” the official added.

Source: https://www.cnbc.com/2026/03/06/fda-reversals-on-uniqure-moderna-approvals-worry-investors.html

Market Opportunity
Shiba Inu Treat Logo
Shiba Inu Treat Price(TREAT)
$0.0002528
$0.0002528$0.0002528
+3.35%
USD
Shiba Inu Treat (TREAT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Landmark Court Ruling Rejects Terrorism Financing Claims

Landmark Court Ruling Rejects Terrorism Financing Claims

The post Landmark Court Ruling Rejects Terrorism Financing Claims appeared on BitcoinEthereumNews.com. Binance Lawsuit Dismissed: Landmark Court Ruling Rejects
Share
BitcoinEthereumNews2026/03/07 10:27
The U.S. Commodity Futures Trading Commission unveiled a new logo, claiming it will usher in a "golden age" of innovation.

The U.S. Commodity Futures Trading Commission unveiled a new logo, claiming it will usher in a "golden age" of innovation.

PANews reported on March 7 that the U.S. Commodity Futures Trading Commission (CFTC) today unveiled a new logo, stating that it symbolizes the agency's commitment
Share
PANews2026/03/07 10:08
MetaMask’s Polymarket Integration May Make LINEA Rewards and Perpetual Trading a New On-Chain Financial Hub

MetaMask’s Polymarket Integration May Make LINEA Rewards and Perpetual Trading a New On-Chain Financial Hub

The post MetaMask’s Polymarket Integration May Make LINEA Rewards and Perpetual Trading a New On-Chain Financial Hub appeared on BitcoinEthereumNews.com. COINOTAG recommends • Exchange signup 💹 Trade with pro tools Fast execution, robust charts, clean risk controls. 👉 Open account → COINOTAG recommends • Exchange signup 🚀 Smooth orders, clear control Advanced order types and market depth in one view. 👉 Create account → COINOTAG recommends • Exchange signup 📈 Clarity in volatile markets Plan entries & exits, manage positions with discipline. 👉 Sign up → COINOTAG recommends • Exchange signup ⚡ Speed, depth, reliability Execute confidently when timing matters. 👉 Open account → COINOTAG recommends • Exchange signup 🧭 A focused workflow for traders Alerts, watchlists, and a repeatable process. 👉 Get started → COINOTAG recommends • Exchange signup ✅ Data‑driven decisions Focus on process—not noise. 👉 Sign up → The MetaMask Polymarket integration brings decentralized prediction markets directly into MetaMask, enabling users to trade event outcomes while retaining full self-custody. The update, paired with in-app perpetuals and a Rewards program, transforms MetaMask into a multi‑product on‑chain trading hub. (Published Oct 14, 2025) MetaMask adds Polymarket prediction markets natively Users can trade outcomes on crypto, politics and global events while keeping custody of private keys. Polymarket has seen nearly $20B in trading volume (TokenTerminal); MetaMask also launches Rewards and in‑app perpetuals. MetaMask Polymarket integration: trade predictions inside MetaMask while keeping custody — explore in‑app perps, earn rewards, and access new trading tools today. The world’s largest self-custodial wallet adds perpetual trading, a rewards system, and a Polymarket integration, signaling its transformation into a full financial hub. COINOTAG recommends • Professional traders group 💎 Join a professional trading community Work with senior traders, research‑backed setups, and risk‑first frameworks. 👉 Join the group → COINOTAG recommends • Professional traders group 📊 Transparent performance, real process Spot strategies with documented months of triple‑digit runs during strong trends; futures plans use defined R:R…
Share
BitcoinEthereumNews2025/10/15 05:19